Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 29;14:3103. doi: 10.1038/s41467-023-38899-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Scheme of aNK1.1 and aVLA4 treatments in C57BL/6 mice. b The percentage of time spent and the frequency of entries in the open arms in elevated plus maze in IgG2a and aNK1.1 treated mice (n = 8 mice per condition; *p = 0.048, **p < 0.001 two-tailed Student’s t test), and IgG2b and aVLA4 treated mice (n = 6 mice per condition, **p < 0.001 two-tailed Student’s t test). Data are expressed as mean ± SEM. c Open-field test (10 min) results for IgG2a-, aNK1.1-, IgG2b-, aVLA4-treated mice (n = 10 IgG2a and aNK1.1, n = 8 IgG2b and aVLA4 mice), and Rag2^−/− and Rag2^−/−γc^−/− mice (n = 7 per condition) showing total distance traveled (*p = 0.039 IgG2a vs aNK1.1 mice, *p = 0.037 IgG2b vs aVLA4 mice, **p = 0.002 Rag2^−/− vs Rag2^−/−γc^−/−), percent time spent in the center (**p < 0.001 IgG2a vs aNK1.1 and IgG2b vs aVLA4 mice, **p = 0.022 Rag2^−/− vs Rag2^−/−γc^−/−), center episodes (p = 0.102 IgG2a vs aNK1.1 mice, p = 0.151 IgG2b vs aVLA4 mice, *p = 0.036 Rag2^−/− vs Rag2^−/−γc^−/−), and the total activity (**p < 0.001 IgG2a vs aNK1.1 and IgG2b vs aVLA4 mice; two-tailed Student’s t test). Data are expressed as mean ± SEM. d Discrimination index analyzed after 1 h (short term memory - STM) and 24 h (long term memory - LTM) in mice treated with IgG2a, aNK1.1, IgG2b and aVLA4 (n = 10 IgG2a and aNK1.1, n = 8 IgG 2b and aVLA4 mice, **p = 0.003 IgG2a vs aNK1.1, **p = 0.004 IgG2b vs aVLA4, one-way ANOVA), and in Rag2^−/− and Rag2^−/−γc^−/− mice (n = 7 mice per condition, *p = 0.011 one-way ANOVA). Data are expressed as mean ± SEM. c, d Open-field test results on distance traveled for IgG2a-treated mice vs Rag2^−/− and Rag2^−/−γc^−/− (**p < 0.01 IgG2a vs Rag2^−/− mice, **p < 0.001 IgG2a vs Rag2^−/−γc^−/− mice, two-way ANOVA). Object novelty discrimination in IgG2a-treated mice vs Rag2^−/− and Rag2^−/−γc^−/− mice (STM **p < 0.001 IgG2a vs Rag2^−/− and Rag2^−/−γc^−/− mice; LTM ^**p < 0.01 IgG2a vs Rag2^−/− mice, two-way ANOVA). Data are representative of at least two experiments with similar results. a, d Figure created with BioRender.com.